Skip to main content
. 2022 Dec 8;9(2):215–224. doi: 10.1001/jamaoncol.2022.5816

Figure 4. One-Stage Pooled Analysis of First-line Studies With the Tumor Proportion Score (TPS) Available (CheckMate-648 and ESCORT-1st).

Figure 4.

A, There was a significant difference in overall survival for the overall population comparing immunochemotherapy (hazard ratio [HR], 0.73; 95% CI, 0.63-0.84; P < .001) with chemotherapy alone. B, There was a significant difference in overall survival for the population with a TPS of 1% or higher comparing immunochemotherapy (HR, 0.57; 95% CI, 0.47-0.70; P < .001) with chemotherapy alone. C, There was no significant difference in overall survival for the subgroup with a TPS lower than 1% comparing immunochemotherapy (HR, 0.91; 95% CI, 0.74-1.12; P = .38) with chemotherapy alone.